-

10:51:02 AM

APLS Stock News

APLS - Apellis Pharmaceuticals Inc

03/06/23 4:05 PM

Nasdaq : APLS

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 6 new employees with a grant date of March 1, 2023, as equity

RHEA-AI

very positive

03/01/23 7:00 AM

Nasdaq : APLS

conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following March investor conferences: Cowen 43rd Annual Healthcare Conference:

RHEA-AI

neutral

02/27/23 5:19 PM

Nasdaq : APLS

offering

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the

RHEA-AI

neutral

02/22/23 9:48 PM

Nasdaq : APLS

offering

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 3,174,603 shares of its common stock at a public offering price of $63.00

RHEA-AI

neutral

02/22/23 7:22 AM

Nasdaq : APLS

offering

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock (or pre-funded warrants to

RHEA-AI

neutral

02/21/23 4:13 PM

Nasdaq : APLS

earnings

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

SYFOVRE™ (pegcetacoplan injection) approved in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) EU marketing authorization application for intravitreal pegcetacoplan validated by the European Medicines Agency; decision by

RHEA-AI

very positive

02/17/23 4:06 PM

Nasdaq : APLS

fda approval

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

SYFOVRE slowed GA progression with increasing effects over time Approved for all patients with GA, with dosing flexibility every 25 to 60 days Well-demonstrated safety profile following ~12,000 injections over 24 months Conference call today at 4:30 p.m. ET A Media Snippet accompanying this

RHEA-AI

neutral

02/13/23 4:05 PM

Nasdaq : APLS

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 8 new employees with a grant date of February 1, 2023, as equity

RHEA-AI

very positive

01/05/23 7:00 AM

Nasdaq : APLS

management

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces

RHEA-AI

neutral

01/03/23 7:00 AM

Nasdaq : APLS

conferences

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m.

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

APLS Data

IndustryPharmaceutical Preparation Manufacturing
Websiteapellis.com
CeoCedric Francois
Security nameApellis Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees476
Tags
- Distribution Services
- Medical Distributors
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address100 Fifth Avenue
StateMassachusetts
CityWaltham
Zip02451
CountryUnited States
Phone16179775700

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.